By Sabela Ojea
Renovaro said it named Nathen Fuentes as its permanent finance chief to succeed interim CFO Simon Tarsh.
The cancer diagnostics and therapeutics company on Tuesday said Fuentes, who previously served as CFO of Telomir Pharmaceuticals, has experience leading acquisition and organic growth initiatives.
The Los Angeles-based company on Monday agreed to acquire Predictive Oncology, which owns a database of 150,000 frozen and live tumor samples and more than 20 years of drug-response data.
In a letter to shareholders, Chief Executive David Weinstein also said Nasdaq notified the company it is now in good standing.
He added that the company has now "taken critical steps in building a point of care cancer detection and vaccine company and will continue to update you regularly on our progress."
Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix
(END) Dow Jones Newswires
January 07, 2025 09:49 ET (14:49 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。